Zacks Investment Research upgraded shares of Synthetic Biologics (NYSEAMERICAN:SYN) from a sell rating to a buy rating in a research report released on Saturday morning. They currently have $0.25 price target on the stock.
According to Zacks, “Synthetic Biologics, Inc. is a biotechnology company focused on the development of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses. The Company is engaged in developing product candidates to treat pulmonary arterial hypertension, relapses in multiple sclerosis, cognitive dysfunction in multiple sclerosis, fibromyalgia and amyotrophic lateral sclerosis. Synthetic Biologics, Inc., formerly known as Adeona Pharmaceuticals, Inc., is headquartered in Ann Arbor, Michigan. “
Separately, Griffin Securities cut Synthetic Biologics from a buy rating to a hold rating in a report on Wednesday, May 9th. Two analysts have rated the stock with a sell rating, one has given a hold rating and two have issued a buy rating to the company’s stock. The stock presently has a consensus rating of Hold and a consensus target price of $2.63.
Synthetic Biologics (NYSEAMERICAN:SYN) last issued its quarterly earnings data on Tuesday, May 8th. The company reported ($0.02) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.03.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in SYN. Citadel Advisors LLC raised its position in shares of Synthetic Biologics by 312.1% in the fourth quarter. Citadel Advisors LLC now owns 241,797 shares of the company’s stock valued at $122,000 after buying an additional 183,120 shares in the last quarter. Virtu Financial LLC raised its position in shares of Synthetic Biologics by 256.1% in the fourth quarter. Virtu Financial LLC now owns 299,577 shares of the company’s stock valued at $152,000 after buying an additional 215,440 shares in the last quarter. Blair William & Co. IL raised its position in shares of Synthetic Biologics by 14.8% in the first quarter. Blair William & Co. IL now owns 1,980,857 shares of the company’s stock valued at $631,000 after buying an additional 255,096 shares in the last quarter. Finally, 683 Capital Management LLC acquired a new stake in shares of Synthetic Biologics in the fourth quarter valued at approximately $762,000.
Synthetic Biologics Company Profile
Synthetic Biologics, Inc, a late-stage clinical company, develops therapeutics designed to preserve the microbiome to protect and restore the health of patients. Its lead product candidates are in Phase III development, such as SYN-004 that is designed to protect the gut microbiome from the effects of commonly used intravenous (IV) beta-lactam antibiotics for the prevention of C.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Synthetic Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthetic Biologics and related companies with MarketBeat.com's FREE daily email newsletter.